

# Subject index of volume 119

"Atypical" neuroleptics 231  
 ABT-418 368  
 Accidents 39  
 Acetylcholine 139  
 Acetylcholinesterase 391  
 Acoustic startle response 71  
 Adaptation 325  
 Adenosine antagonists 99  
 Aggression 353  
 Aging 391  
 Agonist 399  
 Akathisia 1  
 Alcohol 186, 205, 261  
 Alcoholism 261  
 1-allyl-3,7-dimethyl-8-p-sulfoxanthine 99  
 Amitriptyline 277  
 Amphetamine 79, 155  
 Anandamine 282  
 Antagonist correlation analysis 222  
 Antidepressants 15, 47, 440  
 Antinociception 282  
 Antipsychotic agents 133  
 D-AP5 55  
 Apomorphine 79, 414  
 L-Arginine 115  
 Arousal 39  
 Attention 66, 139, 315  
 Atypical neuroleptics 428  
 Auditory evoked potentials 163  
 Autoreceptor 299  
 Behaviour 20  
 Benzodiazepine 105, 399  
 Benzodiazepines 27, 39  
 Buprenorphine 268  
 Buspirone 47  
 Caffeine 66, 99  
 Cannabidiol 282  
 Carbon monoxide 193  
 Cardiovascular effects 205  
 Cat 20  
 Catalepsy 282  
 Chlormethiazole 247  
 Cholinergic system 305  
 Cigarette smoking 349  
 Classical conditioning 414  
 Clozapine 291  
 Cluster analysis 361  
 Cocaine 79, 92, 179  
 Cocaine analogs 376  
 Cocaine base 127  
 Cognition 295  
 Cognitive function 325  
 Combination treatment 342  
 Conditioned place preference 92  
 Conditioned taste aversion 213  
 Consolidation 155  
 Cortisol 311  
 CP-55,940 282  
 D-CPP 55  
 Crack 127  
 Craving 171  
 8-cyclopentyl-1,3-dipropylxanthine 99  
 CYP2D6 genotype and phenotype 345  
 D<sub>1</sub> receptors 79

D<sub>1</sub>-dopamine receptors 1  
 D<sub>2</sub> dopamine receptors 345  
 Delayed response 391  
 Dependence 268  
 Depression 277, 342, 449  
 Desipramine 15, 47  
 5,7-DHT (5,7-dihydroxytryptamine) 9  
 Diazepam 9, 399, 421  
 Dihydroxidine 79  
 2,5-Dimethoxy-4-methylamphetamine (DOM) 239  
 DOI 291  
 DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) 9  
 Dopamine 15, 71, 145, 299  
 Dopamine D<sub>1</sub> and D<sub>2</sub> receptors 34  
 Dopamine D<sub>1</sub> receptor 466  
 Dopamine receptors 145  
 Dopamine transporter 376  
 Dose-response 79  
 Double-blind method 39  
 Drug discrimination 79  
 Drug discrimination 368  
 Drug self-administration 127  
 Drug-induced stimulus control 222  
 Drug-induced stimulus control (DISC) 239  
 d-Tubocurarine 163  
 Ecstasy 247  
 EEG 349, 361  
 Elderly patients 277  
 Electric shock 261  
 Electroconvulsive shock 99  
 Electroconvulsive therapy 440  
 Endogenous opioid systems 92  
 Endozepines 295  
 Epilepsy 115  
 Ethanol 353, 455  
 Ethanol self-administration 186  
 Event-related potentials 455  
 Excitatory amino acid 55  
 Explicit memory 27  
 Factor analysis 361  
 Familial-genetic risk 261  
 Fenfluramine 311  
 FG-8205 399  
 Fixed ratio 127  
 Flumazenil 295  
 Fluoxetine 15  
 Food deprivation 127  
 Food satiation 127  
 Footshock 334  
 Forced swim test 47  
 Free recall 155  
 GABA 20, 105  
 Gender differences 205  
 Globus pallidus 20  
 Glutamate 20  
 Glycine 55  
 Grooming 145  
 (R)-HA-966 55  
 Haloperidol 34, 124, 213  
 Head shake 9  
 Heroin 334  
 Hippocampus 282

5-HT 47  
 5-HT<sub>1A</sub> agonists 47  
 5-HT<sub>1A</sub> receptors 311  
 5-HT<sub>2</sub> receptors 345  
 5-HT<sub>2A</sub> 9, 222  
 5-HT<sub>2C</sub> 222  
 5-HT<sub>2C</sub> receptor 466  
 5-HT<sub>3</sub> antagonist 186  
 5-HT<sub>3</sub> receptor antagonists 213  
 5-HT<sub>4</sub> 186  
 Human 105, 345, 353  
 Human memory 155  
 Humans 305, 405, 455  
 Hunger reduction 414  
 6-Hydroxydopamine 145, 466  
 5-Hydroxytryptamine 247  
 Hyperthermia 247  
 Hypoglycemia 325  
 ICI 204 636 231  
 Immobilization stress 9  
 In vivo microdialysis 334  
 Individual variation 361  
 Information processing 455  
 Intravenous drug self-administration 334  
 [<sup>3</sup>H]Ketanserin binding 9  
 Kindling 115  
 Latent inhibition 414  
 Liver 295  
 Locomotion 145, 299  
 Locomotor activity 213, 428  
 Locus of control 449  
 Lorazepam 105, 315  
 LTP 115  
 Lysergic acid diethylamide (LSD) 239  
 Male rat sexual behaviour 291  
 Males 261  
 Man 311  
 m-Chlorophenylpiperazine 466  
 m-Chlorophenylpiperazine (mCPP) 222  
 MDMA 247  
 Mecamylamine 213, 368  
 Memory 66, 315, 391, 405  
 Mesocorticolimbic DA system 71  
 Methadone 268  
 Methamphetamine 34  
 3,4-Methylenedioxymethamphetamine 247  
 Microdialysis 15  
 Mitochondrial impairment 474  
 Monoamine oxidase inhibitors 342  
 Mood 66  
 Morphine 186  
 Mouse ambulation 34  
 Mouse striatum 376  
 Muscarinic 139  
 N. accumbens 428  
 Naloxone 92  
 Naltrexone 334  
 L-NAME 115  
 Nausea 1  
 Neostriatum 145  
 Neuroglycopenia 325  
 Neuroleptics 247  
 Neuropsychology 295  
 Neurotoxicity 247  
 Nicotine 124, 205, 213, 305, 368, 385, 405

# Subject index of volume 119

"Atypical" neuroleptics 231  
 ABT-418 368  
 Accidents 39  
 Acetylcholine 139  
 Acetylcholinesterase 391  
 Acoustic startle response 71  
 Adaptation 325  
 Adenosine antagonists 99  
 Aggression 353  
 Aging 391  
 Agonist 399  
 Akathisia 1  
 Alcohol 186, 205, 261  
 Alcoholism 261  
 1-allyl-3,7-dimethyl-8-p-sulfoxanthine 99  
 Amitriptyline 277  
 Amphetamine 79, 155  
 Anandamine 282  
 Antagonist correlation analysis 222  
 Antidepressants 15, 47, 440  
 Antinociception 282  
 Antipsychotic agents 133  
 D-AP5 55  
 Apomorphine 79, 414  
 L-Arginine 115  
 Arousal 39  
 Attention 66, 139, 315  
 Atypical neuroleptics 428  
 Auditory evoked potentials 163  
 Autoreceptor 299  
 Behaviour 20  
 Benzodiazepine 105, 399  
 Benzodiazepines 27, 39  
 Buprenorphine 268  
 Buspirone 47  
 Caffeine 66, 99  
 Cannabidiol 282  
 Carbon monoxide 193  
 Cardiovascular effects 205  
 Cat 20  
 Catalepsy 282  
 Chlormethiazole 247  
 Cholinergic system 305  
 Cigarette smoking 349  
 Classical conditioning 414  
 Clozapine 291  
 Cluster analysis 361  
 Cocaine 79, 92, 179  
 Cocaine analogs 376  
 Cocaine base 127  
 Cognition 295  
 Cognitive function 325  
 Combination treatment 342  
 Conditioned place preference 92  
 Conditioned taste aversion 213  
 Consolidation 155  
 Cortisol 311  
 CP-55,940 282  
 D-CPP 55  
 Crack 127  
 Craving 171  
 8-cyclopentyl-1,3-dipropylxanthine 99  
 CYP2D6 genotype and phenotype 345  
 D<sub>1</sub> receptors 79

D<sub>1</sub>-dopamine receptors 1  
 D<sub>2</sub> dopamine receptors 345  
 Delayed response 391  
 Dependence 268  
 Depression 277, 342, 449  
 Desipramine 15, 47  
 5,7-DHT (5,7-dihydroxytryptamine) 9  
 Diazepam 9, 399, 421  
 Dihydroxidine 79  
 2,5-Dimethoxy-4-methylamphetamine (DOM) 239  
 DOI 291  
 DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) 9  
 Dopamine 15, 71, 145, 299  
 Dopamine D<sub>1</sub> and D<sub>2</sub> receptors 34  
 Dopamine D<sub>1</sub> receptor 466  
 Dopamine receptors 145  
 Dopamine transporter 376  
 Dose-response 79  
 Double-blind method 39  
 Drug discrimination 79  
 Drug discrimination 368  
 Drug self-administration 127  
 Drug-induced stimulus control 222  
 Drug-induced stimulus control (DISC) 239  
 d-Tubocurarine 163  
 Ecstasy 247  
 EEG 349, 361  
 Elderly patients 277  
 Electric shock 261  
 Electroconvulsive shock 99  
 Electroconvulsive therapy 440  
 Endogenous opioid systems 92  
 Endozepines 295  
 Epilepsy 115  
 Ethanol 353, 455  
 Ethanol self-administration 186  
 Event-related potentials 455  
 Excitatory amino acid 55  
 Explicit memory 27  
 Factor analysis 361  
 Familial-genetic risk 261  
 Fenfluramine 311  
 FG-8205 399  
 Fixed ratio 127  
 Flumazenil 295  
 Fluoxetine 15  
 Food deprivation 127  
 Food satiation 127  
 Footshock 334  
 Forced swim test 47  
 Free recall 155  
 GABA 20, 105  
 Gender differences 205  
 Globus pallidus 20  
 Glutamate 20  
 Glycine 55  
 Grooming 145  
 (R)-HA-966 55  
 Haloperidol 34, 124, 213  
 Head shake 9  
 Heroin 334  
 Hippocampus 282

5-HT 47  
 5-HT<sub>1A</sub> agonists 47  
 5-HT<sub>1A</sub> receptors 311  
 5-HT<sub>2</sub> receptors 345  
 5-HT<sub>2A</sub> 9, 222  
 5-HT<sub>2C</sub> 222  
 5-HT<sub>2C</sub> receptor 466  
 5-HT<sub>3</sub> antagonist 186  
 5-HT<sub>3</sub> receptor antagonists 213  
 5-HT<sub>4</sub> 186  
 Human 105, 345, 353  
 Human memory 155  
 Humans 305, 405, 455  
 Hunger reduction 414  
 6-Hydroxydopamine 145, 466  
 5-Hydroxytryptamine 247  
 Hyperthermia 247  
 Hypoglycemia 325  
 ICI 204 636 231  
 Immobilization stress 9  
 In vivo microdialysis 334  
 Individual variation 361  
 Information processing 455  
 Intravenous drug self-administration 334  
 [<sup>3</sup>H]Ketanserin binding 9  
 Kindling 115  
 Latent inhibition 414  
 Liver 295  
 Locomotion 145, 299  
 Locomotor activity 213, 428  
 Locus of control 449  
 Lorazepam 105, 315  
 LTP 115  
 Lysergic acid diethylamide (LSD) 239  
 Male rat sexual behaviour 291  
 Males 261  
 Man 311  
 m-Chlorophenylpiperazine 466  
 m-Chlorophenylpiperazine (mCPP) 222  
 MDMA 247  
 Mecamylamine 213, 368  
 Memory 66, 315, 391, 405  
 Mesocorticolimbic DA system 71  
 Methadone 268  
 Methamphetamine 34  
 3,4-Methylenedioxymethamphetamine 247  
 Microdialysis 15  
 Mitochondrial impairment 474  
 Monoamine oxidase inhibitors 342  
 Mood 66  
 Morphine 186  
 Mouse ambulation 34  
 Mouse striatum 376  
 Muscarinic 139  
 N. accumbens 428  
 Naloxone 92  
 Naltrexone 334  
 L-NAME 115  
 Nausea 1  
 Neostriatum 145  
 Neuroglycopenia 325  
 Neuroleptics 247  
 Neuropsychology 295  
 Neurotoxicity 247  
 Nicotine 124, 205, 213, 305, 368, 385, 405

- Nicotine dependence 171  
 Nicotine gum 193  
 Nicotinic 139  
 Nicotinic acetylcholine receptors 368  
 Nitric oxide 115  
 L-Nitro-arginine 115  
 3-Nitropropionic acid 474  
 NNC 756 1  
 Non-human primates 391  
 Nonlinearity 349  
 8-OH-DPAT 47  
 Olanzapine 133  
 Olfactory tubercle 428  
 Onset of action 440  
 Opiate 186  
 Opioid 268  
 Opioid drugs 334  
 Oral activity 466  
 Oro-facial dyskinesia 20  
 P300 455  
 Pain 261  
 Parkinsonism 55  
 Parkinson's disease 145  
 Paroxetine 277  
 Partial agonist 399  
 Paw test 428  
 Pecking 414  
 Perceptual speed 305  
 Pharmac-EEG 231  
 Phenylpropanolamine 85  
 Pigeons 414  
 Pindolol 311  
 Placebo effect 449  
 Positron emission tomography 1, 345  
 Post-methamphetamine treatment 34  
 Prefrontal cortex 15  
 Prefrontal neocortex 139  
 Prepulse inhibition 71  
 Problem solving 66  
 Progressive ratio 127  
 Prolactin 231, 311  
 Psychomotor speed 295  
 Psychomotor tests 39  
 Punished responding 133  
 Quinpirole 299  
 Radial-arm maze 282  
 Rat 71, 139, 299, 399  
 Rating scales 449  
 Rats 79, 99, 186, 474  
 Reaction time 295  
 Receptors 139  
 Rectal temperature 282  
 Reflective processes 27  
 Refractory depression 342  
 Reinforcement 193  
 Reinforcement mechanism 414  
 Reinforcing efficacy 127  
 Reinstatement 334  
 Relapse 334  
 Repeated administration 34  
 Rhesus monkey 421  
 Rhesus monkeys 127  
 Risperidone pharmacokinetics 345  
 SCH 23390 1, 34, 79  
 Schizophrenia 71, 124, 163, 231  
 Scopolamine 315  
 Sedation 27  
 Seizures 99, 115  
 Selective serotonin reuptake inhibitors 277  
 Self-administration 385  
 Sensitization 34, 414  
 Sensory gating 163  
 Serial probe recognition task 421  
 Seroquel 231  
 Serotonin 15, 71, 179, 353  
 Serotonin (5-HT) 222  
 Serotonin receptors 291  
 Serotonin selective reuptake inhibitors 342  
 Side effects 39  
 SKF 38393 79, 466  
 Smokers 205  
 Smoking 85, 124, 127, 361, 385  
 Smoking cessation 171  
 Smoking self-report 193  
 State-dependency 399  
 Stress 334  
 Striatum 466  
 Subjective effects 205  
 Subjective responses 385  
 Substantia nigra 145  
 Subthalamic nucleus 20  
 Sulpiride 299  
 Supersensitivity 466  
 Symptoms of hypoglycemia 325  
 Tardive dyskinesia 474  
 $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC) 282  
 Thigmotactic scanning 145  
 Time course 440  
 Tolerance 385, 414  
 Topography 361  
 Treatment of depression 342  
 Triazolam 27  
 Tropisetron 186  
 Tryptophan 179, 353  
 Tryptophan depletion 353  
 Turning 145  
 Type 1 diabetes 325  
 Urges 171  
 Vacuous chewing movements 474  
 Ventral tegmental area 368  
 Vigilance 315  
 Vigilance performance 39  
 Visual perception 105  
 Weight 85  
 WIN-55,212-2 282  
 Withdrawal 268, 334  
 Working memory 139  
 Zolpidem 399